Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
9.0
4.9
Journals
IJMS
Special Issues
Molecular Advances in Biomarkers of Central Nervous System Diseases and...
ijms-logo
Submit to Special Issue Submit Abstract to Special Issue Review for IJMS Propose a Special Issue

Journal Menu

► Journal Menu

Journal Browser

► Journal Browser
share announcement

Molecular Advances in Biomarkers of Central Nervous System Diseases and Disorders

A special issue of International Journal of Molecular Sciences (ISSN 1422-0067). This special issue belongs to the section "Molecular Neurobiology".

Deadline for manuscript submissions: 30 November 2025 | Viewed by 1385

Special Issue Editors

Prof. Dr. David Gurwitz

E-Mail Website
Guest Editor
Department of Human Molecular Genetics and Biochemistry, Faculty of Health and Medical Sciences, Tel Aviv University, Tel Aviv 69978, Israel
Interests: pharmacogenomics; RNA biomarkers; psychiatric disorders; autism spectrum disorder; Alzheimer’s disease; health aging
Special Issues, Collections and Topics in MDPI journals
Dr. Chiara Villa

E-Mail Website
Guest Editor
Department of Medicine and Surgery, University of Milano-Bicocca, Monza, Italy
Interests: genetics; Alzheimer’s disease; non-coding RNAs; neurodegeneration; epilepsy; brain; biomarkers
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

IJMS is pleased to announce a Special Issue titled “Molecular Advances in Biomarkers of Central Nervous System Diseases”.

For this Special Issue, our Guest Editors, Prof. Dr. David Gurwitz and Dr. Chiara Villa, will consider articles exploring novel biomarkers for early diagnosis, prognosis, differential diagnosis of disease subtypes, and personalized treatment choice for CNS diseases and disorders. Topics of interest include Alzheimer’s disease, Parkinson’s disease, stroke, epilepsy, and metabolic or genetic disorders affecting CNS function.

This Special Issue encompasses original research, opinion, and review articles. Studies with either human samples from patients and matched controls or established animal models of CNS diseases and disorders are particularly encouraged.

Biomarkers may include DNA methylation profiles, modified expression levels of mRNA, microRNAs, or other non-coding RNAs affecting CNS disease risk, age of onset, severity, prognosis, or response to approved or experimental therapeutics. In addition to DNA and RNA biomarkers, studies may include protein, metabolome, microbiome, and mitochondrial biomarkers affecting the aforementioned parameters of CNS diseases and disorders.

Reports on approved clinical trials will be considered when based on new mechanisms for a given CNS disease or disorder.

Prof. Dr. David Gurwitz
Dr. Chiara Villa
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. International Journal of Molecular Sciences is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. There is an Article Processing Charge (APC) for publication in this open access journal. For details about the APC please see here. Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • RNA biomarkers
  • CNS disorders
  • autism spectrum disorder
  • precision medicine

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (1 paper)

Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

19 pages, 967 KB  
Article
Real-World Laboratory Analysis of Molecular Biomarkers in Multiple Sclerosis Centers in Central-Eastern European Countries Covering 107 Million Inhabitants
by Anett Járdánházy, Thomas Berger, Harald Hegen, Bernhard Hemmer, Halina Bartosik-Psujek, Vanja Basic Kes, Achim Berthele, Jelena Drulovic, Mario Habek, Dana Horakova, Alenka Horvat Ledinek, Eva Kubala Havrdova, Melinda Magyari, Konrad Rejdak, Cristina Tiu, Peter Turcani, Krisztina Bencsik, Zsigmond Tamás Kincses and László Vécsei
Int. J. Mol. Sci. 2025, 26(17), 8274; https://doi.org/10.3390/ijms26178274 - 26 Aug 2025
Viewed by 766
Abstract
A multicenter molecular biomarker survey was conducted in Multiple Sclerosis (MS) centers across Central-Eastern European countries, encompassing a population of 107 million. Our aim was to provide a “snapshot” for future studies investigating the use of molecular biomarkers in MS. A self-report questionnaire [...] Read more.
A multicenter molecular biomarker survey was conducted in Multiple Sclerosis (MS) centers across Central-Eastern European countries, encompassing a population of 107 million. Our aim was to provide a “snapshot” for future studies investigating the use of molecular biomarkers in MS. A self-report questionnaire was distributed via email to MS centers in seven Central-Eastern European countries (Croatia, Czech Republic, Poland, Romania, Serbia, Slovakia, and Slovenia) and to four reference centers (two in Austria, one in Germany, and one in Denmark), focusing on cerebrospinal fluid (CSF) analysis and molecular biomarkers in MS. Responding centers routinely request CSF oligoclonal band (OCB) testing in suspected MS cases, although no consensus exists on the number of CSF-restricted bands required to define OCB positivity, either within or between countries. More than half of the surveyed centers in the Czech Republic, Slovakia, Slovenia, and the reference centers request kappa free light chain (κFLC) testing in patients with suspected MS. Neurofilament light chain (NfL) is frequently used as a molecular biomarker for MS in Romania, Slovakia, and the reference centers. In summary, besides the use of CSF-specific OCB there is no consensus among the surveyed countries regarding the use of molecular biomarkers in MS. Full article
(This article belongs to the Special Issue Molecular Advances in Biomarkers of Central Nervous System Diseases and Disorders)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-1
Back to TopTop